Retrospective Study of Adjuvant Chemotherapy Effects on Survival Rate after Three-Field Lymph Node Dissection for Stage IIA Esophageal Cancer

To determine the efficacy of postoperative adjuvant chemotherapy with paclitaxel plus cisplatin (Taxol + DDP, TP therapy) for stage IIA esophageal squamous cell carcinoma (ESCC) and to investigate the expression of RUNX3 in lymph node metastasis-negative esophageal cancer and its relationship with medical prognosis, a retrospective summary of clinical treatment of 143 cases of stage IIA esophageal squamous cell carcinoma patients was made. The patients were divided into two groups, a surgery alone control group (52 patients) and a chemotherapy group that received postoperative TP therapy (91 patients). The disease-free and 5 year survival rates were compared between the groups and a multivariate analysis of prognostic factors was performed. The same analysis was performed for cases classified as RUNX3 positive and negative, with post-operative specimens assessed by immunohistochemistry. Although the disease-free and 5 year survival rates in control and chemotherapy groups did not significantly differ and there was no significance in RUNX3 negative cases, postoperative adjuvant chemotherapy in the chemotherapy group was shown to improve disease-free and 5 year survival rate compared to the control group in RUNX3 positive cases. On Cox regression multivariate analysis, postoperative adjuvant chemotherapy ( P <0.01) was an independent prognostic factor for RUNX3 positive cases, suggesting that postoperative TP may be effective as adjuvant chemotherapy for stage IIA esophageal cancer patients with RUNX3 positive lesions.


Introduction
Esophageal squamous cell cancer (ESCC) accounts for about 90% of all esophageal cancer diagnosed in China, as technology evolves, many ESCC patients are detected cancer at early stage in China (Lu et al., 2014). Surgical resection still remains the preferred treatment and the best choice for ESCC (Mirinezhad et al., 2014). Despite of surgery alone is usually curative for early stage tumor, the 5 year survival rate of those postoperative patients remains low, even after extended surgery (Mariette et al., 2007). Therefore, a multimodal approach, including postopera-tive adjuvant therapy, is essential to further improve operation successs rate for ESCC patients.
Paclitaxel plus Cisplatin (Taxol+DDP, TP regimen) therapy has been clearly demonstrated to be a viable option in the postoperative adjuvant chemotherapy setting for patients with lymph node metastasis from esophageal cancer (Leonard et al., 2004). However, the role of adjuvant chemotherapy for lymph node metastasisnegative esophageal cancer is still unclear. Few clinicians have studied the survival advantage conferred on patients Department of Thoracic Surgery, Provincial Hospital Affiliated to Shandong University, Jinan, China *For correspondence: wz620226@hotmail.com

Retrospective Study of Adjuvant Chemotherapy Effects on Survival Rate after Three-Field Lymph Node Dissection for Stage IIA Esophageal Cancer
Hua-Xia Chen, Zhou Wang* with stage IIA disease by Adjuvant chemotherapy (Ando et al., 2003). As an important tumor suppressor gene, RUNX3 is found in many different types of cancer, many studies have demonstrated that ESCC cells with RUNX3 up-regulated had a significantly improved chemotherapeutic sensitivity as compared with RUNX3 negative control (Hiramatsu et al., 2005).
In this study, we used the clinical data, combined with follow-up results, analyzed the efficacy of treatment with TP therapy as postoperative adjuvant chemotherapy in stage IIA middle thoracic ESCC patients who underwent Ivor-Lewis surgery with three-field lymph node dissection. The patients were also grouped according to RUNX3 expression in order to identify a subgroup that may benefit from chemotherapy therapy. The purpose of this study was to explore RUNX3 expression to predict chemotherapy sensitivity of stage IIA ESCC after esophagectomy and to provide the basis for adopting targeted adjuvant treatment in these patients, determine which patient subgroups among patients with RUNX3 expression may benefit from TP as postoperative adjuvant chemotherapy.

Case selection
A total of surgical specimens were collected from 143 patients with stage IIA middle thoracic ESCC who underwent Ivor-Lewis surgery with three-field lymph node dissection in the Department of Thoracic Surgery, Provincial Hospital Affiliated to Shandong University from January 2005 to January 2008. The inclusion criteria were as follows: i) No residual tumor cells on upper or lower cutting edge checked by pathology, lateral margins with no residual focus, the number of lymph nodes dissected was more than nine; ii) The tumors were diagnosed histologically as squamous cell carcinoma, disease stage redetermined according to the tumor, node, metastasis staging system (TNM) classification established by Union for International Cancer Control (UICC) in 2009, all patients had stage IIA (pT2, 3N0M0) disease; iii) no preoperative treatment (chemotherapy, radiotherapy or chemoradiotherapy); iv) complete 5 year follow-up review; v) no perioperative complications; vi) postoperative time to chemotherapy >2 weeks and <2 months; vii) All patients and their relatives provided the informed consent, and the protocol was approved by the ethical committee of our institution.

Grouping and Adjuvant chemotherapy regimen
The patients were divided into two groups, a surgery alone group (Control group, 91 patients) and a group that received postoperative chemotherapy (Chemotherapy group, 52 patients). The postoperative adjuvant chemotherapy included Taxol 135 mg/m 2 on day 1 and DDP 75 mg/m 2 on day 1, completed at least 4 chemotherapy cycles, 21 days as one cycle. After RUNX3 protein expression detection by immunohistochemistry studies and western-blot in postoperative tumor specimens, patients were divided into RUNX3 positive group and RUNX3 negative group and the 5 year survival were analyzed separately.

Statistical analysis
SPSS 19.0 computer software was used to construct a database. Survival difference was compared by χ 2 test, the Kaplan-Meier method was performed to calculate the survival rate. Cox regression multivariate analyses were performed to identify independent prognostic factors.

Clinicopathological factors
The clinicopathological characteristics of the 143 patients are summarized in Table 1. There were no significant differences between the Control (91 patients) and Chemotherapy (52 patients) groups regarding clinicopathological factors. By immunohistochemical staining, the positive expression of RUNX3 protein showed as yellow or brownish yellow stain in the cytoplasm and/or nucleus of tumor cells. In143 ESCC tissue samples, 83 were detected with RUNX3-positive expression: 28 RUNX3 nuclei expression and 55 RUNX3 cytoplasmic expression (Figure 1).

Chemotherapy efficacy
The disease-free survival was 38.5% in the Control group (35/91) and 53.8% (28/52) in the Chemotherapy group, with no statistically significant difference (P=0.099), the overall 5 year survival was 34.1% (31/91) in the Control group and 46.2% (24/52) in the Chemotherapy group, also without a statistically significant difference (P=0.109) ( Figure 1B). By Cox regression multivariate analyses, the T-status (P<0.01), RUNX3 expression (P<0.05) were identified as prognostic factors in all the patients (Table 1B). In RUNX3 negative subgroups (n=60), no significant difference was observed in disease-free survival (P=0.870) and the 5 year survival (P=0.992) between the Control and Chemotherapy groups ( Figure. 2B). By Cox regression multivariate analyses, only T-status (P<0.01) was identified as prognostic factors in all the patients (Table 2B). On the other hand, in RUNX3 positive subgroups (n=83), the disease-free survival was 34.5% in the Control group (20/58) and 64.0% (16/25) in the Chemotherapy group, with statistically significant difference (P=0.021). And the survival was 39.7% (23/58) in the Control group and 68.0% (17/25) in the Chemotherapy group, with a significantly better prognosis in the Chemotherapy group (P=0.011) ( Figure 3B). By Cox regression multivariate analyses, the T-status (P<0.01), TP therapy (P<0.05) were identified as prognostic factors in all the patients (Table 3B).

Discussion
Surgical resection with three-field lymph node dissection is the international standard treatment for many stage IIA thoracic esophageal cancer and certain results have been achieved, but the effect of the surgery alone is not satisfactory: the postoperative 5 year survival rate is only 30-50% (Lau et al., 2006). There are some surely therapeutic effects for postoperative adjuvant chemotherapy cisplatin combine with paclitaxel (TP therapy) on ESCC patients with lymph node involvement or metastases, such as stage III (Song et al., 2014), and it was comfirmed that TP therapy can improve 5 year survival rate in advanced tumors (Ozcelik et al., 2010). TP therapy has been applied widely as the first-line drug of ESCC adjuvant chemotherapy, and is currently recommended as standard therapy (Raspagliesi et al., 2014). But the adjuvant chemotherapy has not been demonstrated to take advantage in early stage of ESCC, especially stage IIA disease (tumors extending through the muscularis propria or adventitia, but without lymph node involvement or metastases), and the Current National Comprehensive Cancer Network (NCCN) of esophageal cancer guidelines suggests patients not to be received adjuvant therapy after tumor complete resection (Tadasuke et al., 2014). For patients with stage IIA esophageal cancer, the use of adjuvant chemotherapy remains controversial, many tumors with similar histopathologic features show significantly different clinical outcomes, it may be appropriate in a subset of individuals at high risk for disease recurrence. Therefore, making the identification of molecular prognostic markers to supplement conventional pathologic staging is desirable. The significance of detecting a reasonable molecule as novel biomarker has already been emphasized.
In recent years, many tumor biology studies have led to the discovery of new and potentially useful molecular markers associated with efficacy of chemotherapy and prognosis of esophageal cancer, the identification of accurate and validated predictive and prognostic markers will help guide the clinician in making informed decisions regarding the appropriate use of adjuvant chemotherapy in patients with stage IIA ESCC, it may help to define better those high risk groups who stand to benefit from adjuvant chemotherapy (Tonomoto et al., 2007).
RUNX3 is a target gene of TGF-b-mediated tumor suppressor pathway. Given the potential role of RUNX3 in TGF-b signaling, it is possible that the tumor suppressor activity of RUNX3 is realized by regulating cell migration and invasion . More and more studies during recent years discovered that RUNX3 inactivation is a crucial factor to determine cancer pathogenesis and clinical outcome in a variety of cancer types, such as gastric, colonic, prostate, breast, lung and bladder cancers (Araki et al., 2005;Suzuki et al., 2005;Ogino et al., 2007;Jiang et al., 2008;Hsu et al., 2009;Wongpaiboonwattana W et al., 2013). It was also reported in esophageal cancer (Sugiura et al., 2008). Much is known about the expression of RUNX3 in esophageal cancer, but less is known about the relationship between RUNX3 expression, chemotherapeutic effect and the prognosis of patients. Previous studies have shown that RUNX3 hypermethylation is related with the cisplatin tolerance of ESCC cells (Cho et al., 2014). After treated with the Methods 5-azacyfidine (5-aza), restoring the expression of RUNX3 can enhance bladder cancer cells apoptosis, and the cytotoxic effect of cisplatin on bladder cancer cells was increased in vitro (Yan et al., 2012). The results showed that the RUNX3 plays a role in the development resistance to cisplatin of bladder cancer. In gastric cancer, paclitaxel can induce RUNX3 expression, the mechanism of paclitaxel may be related with the increasing of RUNX3 expression (Miyagawa et al., 2006).
No significant difference was observed in diseasefree survival and the overall 5 year survival between the Control and Chemotherapy groups when considering the entire patient sample, which the previous study. Various clinicopathological factors were analyzed for the survival of Stage IIA esophageal cancer. Traditional   clinical indicators T-tstatus attempting to stratify stage IIA esophageal cancer patients as high risk factor in identifying patients which were more likely to benefit from adjuvant chemotherapy. RUNX3 expression in Stage IIA esophageal cancer was also found to be signifi¬cantly associated with poor prognosis factors, such as T-status. These results fit nicely with the previous studies, which revealed that the low expression of RUNX3 in primary gastric cancer was associated with a significantly shorter survival (Gao et al., 2010).
There were 83 RUNX3 positive cases and 60 RUNX3 negative cases are summarized in this research, respectively. In the RUNX3 positive cases, the treatment outcomes regarding have a significant difference of the disease-free survival and overall 5 year survival between the Control and Chemotherapy group was only observed in RUNX3 positive cases. Therefore, postoperative adjuvant therapy with Chemotherapy was shown to be beneficial in RUNX3 positive cases.
In conclusion, a loss or substantial decrease of RUNX3 expression was observed in part of stage IIA patients, and expression of RUNX3 was significantly associated with effectiveness of chemotherapy. This study concluded that postoperative adjuvant chemotherapy is useful for stage IIA RUNX3 positive ESCC patients, RUNX3 could be used as a potential molecular postoperative chemotherapy marker for early stage esophageal cancer.